As shown in Table 3, Anti-TNF inhibitors (e.g., etanercept, adalimumab, infliximab) have been associated with a significantly reduced risk of AD in patients with RA [146, 347-349]. The gene discussed is TNF; the disease is rheumatoid arthritis.